Nav: Home

Zika inhibits the proliferation of prostate cancer cells

January 20, 2020

The study was led by Rodrigo Ramos Catharino, a professor in UNICAMP's School of Pharmaceutical Sciences.

In experiments with a human prostate adenocarcinoma cell line (PC-3), the scientists found that Zika inhibits tumor cell proliferation even when inactivated by high temperature. Results of their research, which is supported by São Paulo Research Foundation - FAPESP, have been published) in Scientific Reports.

"The next step in the investigation involves tests in animals. If the results are positive, we plan to look for companies with which to partner on clinical trials," said Catharino, who also works as principal investigator for UNICAMP's Innovare Biomarker Laboratory.

The research project coordinated by Catharino began in 2015, when the link between the Zika epidemic and the rising number of microcephaly cases in Northeast Brazil was discovered. After studies confirmed that Zika can infect and destroy neural progenitor cells, which are precursors of the various types of brain cells in the fetus, Catharino decided to determine the effects of the virus on glioblastoma cells. Glioblastoma is the most common and aggressive type of central nervous system cancer in adults (read more at agencia.fapesp.br/27166).

The positive in vitro results obtained by the UNICAMP group were confirmed in an animal model by scientists at the Human Genome and Stem Cell Research Center (HUG-CELL), a Research, Innovation and Dissemination Center (RIDC) supported by FAPESP and hosted by the University of São Paulo - USP (read more at agencia.fapesp.br/27677).

"Because it's been confirmed that Zika is sexually transmitted and prefers infecting reproductive cells, we now want to test its effectiveness against prostate cancer," Innovare laboratory team member Jeany Delafiori told Agência FAPESP. Catharino is Delafiori's PhD thesis advisor.

The research is also supported by the Obesity and Comorbidities Research Center (OCRC), another of FAPESP's RIDCs, in this case hosted by UNICAMP.

Persistent inflammation

In another recent study published in Scientific Reports, Catharino and his group reported the identification of markers of neurological inflammation as many as two years after birth in the saliva of babies born with microcephaly to mothers diagnosed with Zika during pregnancy.

"This shows that Zika induces inflammation that lasts a long time, persisting even after the virus has been completely eliminated from the organism," Catharino said. "The 'wild' version of the virus [without inactivation] could therefore have undesirable effects and won't be usable therapeutically."

The researchers therefore decided to determine whether Zika retains the capacity to destroy tumor cells after inactivation. The experiments were performed with a viral lineage obtained from samples isolated from a patient infected in the northeastern state of Ceará in 2015. After cultivation in the laboratory, the virus was fused with a nanoparticle and heated to 56 °C for one hour to suppress its infection potential.

The next step was to expose cultured PC-3 (prostate cancer) cells to the inactivated virus for 24 or 48 hours and then compare these treated cells with tumor cells that had not been exposed to the pathogen.

"We observed a selective cytostatic effect [inhibition of cell growth and division] in PC-3 cells. In the analysis performed after 48 hours, the cells in contact with the inactivated virus were found to have grown 50% less than the control cells," Delafiori said.

To investigate how Zika alters tumor cell metabolism, the cultured cells were analyzed with a mass spectrometer, a device that acts as a kind of molecular scale, identifying and sorting elements present in biological samples according to their mass.

To process the large volume of data obtained by mass spectrometry, the researchers performed a multivariate statistical analysis known as PLS-DA (partial least squares discriminant analysis), which pinpointed 21 markers capable of describing how the virus affects tumor cell metabolism and inhibits cell proliferation.

"For example, we identified lipid markers involved in stress and cellular death processes, such as ceramides and phosphatidylethanolamine," Catharino said. "These and other reported markers explain the lipid remodeling induced by the particle and the disruption of metabolic pathways involving molecules such as porphyrin and folic acid, thus contributing to cell stress and the observed antiproliferative effect."

According to Catharino, these 21 metabolites can be used to pursue a better understanding of the biochemical changes triggered by the virus and to identify therapeutic targets, revealing prospects for further research.
-end-
In addition to Delafiori, Carlos Fernando Odir Rodrigues Melo also took part in the project, with a PhD scholarship from FAPESP and supervision by Catharino.

About São Paulo Research Foundation (FAPESP)

The São Paulo Research Foundation (FAPESP) is a public institution with the mission of supporting scientific research in all fields of knowledge by awarding scholarships, fellowships and grants to investigators linked with higher education and research institutions in the State of São Paulo, Brazil. FAPESP is aware that the very best research can only be done by working with the best researchers internationally. Therefore, it has established partnerships with funding agencies, higher education, private companies, and research organizations in other countries known for the quality of their research and has been encouraging scientists funded by its grants to further develop their international collaboration. You can learn more about FAPESP at http://www.fapesp.br/en and visit FAPESP news agency at http://www.agencia.fapesp.br/en to keep updated with the latest scientific breakthroughs FAPESP helps achieve through its many programs, awards and research centers. You may also subscribe to FAPESP news agency at http://agencia.fapesp.br/subscribe.

Fundação de Amparo à Pesquisa do Estado de São Paulo

Related Prostate Cancer Articles:

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.
Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.
The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.
Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.
First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.
Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.
CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.
Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.
Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.
ASCO and Cancer Care Ontario update guideline on radiation therapy for prostate cancer
The American Society of Clinical Oncology (ASCO) and Cancer Care Ontario today issued a joint clinical practice guideline update on brachytherapy (internal radiation) for patients with prostate cancer.
More Prostate Cancer News and Prostate Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: The Power Of Spaces
How do spaces shape the human experience? In what ways do our rooms, homes, and buildings give us meaning and purpose? This hour, TED speakers explore the power of the spaces we make and inhabit. Guests include architect Michael Murphy, musician David Byrne, artist Es Devlin, and architect Siamak Hariri.
Now Playing: Science for the People

#576 Science Communication in Creative Places
When you think of science communication, you might think of TED talks or museum talks or video talks, or... people giving lectures. It's a lot of people talking. But there's more to sci comm than that. This week host Bethany Brookshire talks to three people who have looked at science communication in places you might not expect it. We'll speak with Mauna Dasari, a graduate student at Notre Dame, about making mammals into a March Madness match. We'll talk with Sarah Garner, director of the Pathologists Assistant Program at Tulane University School of Medicine, who takes pathology instruction out of...
Now Playing: Radiolab

What If?
There's plenty of speculation about what Donald Trump might do in the wake of the election. Would he dispute the results if he loses? Would he simply refuse to leave office, or even try to use the military to maintain control? Last summer, Rosa Brooks got together a team of experts and political operatives from both sides of the aisle to ask a slightly different question. Rather than arguing about whether he'd do those things, they dug into what exactly would happen if he did. Part war game part choose your own adventure, Rosa's Transition Integrity Project doesn't give us any predictions, and it isn't a referendum on Trump. Instead, it's a deeply illuminating stress test on our laws, our institutions, and on the commitment to democracy written into the constitution. This episode was reported by Bethel Habte, with help from Tracie Hunte, and produced by Bethel Habte. Jeremy Bloom provided original music. Support Radiolab by becoming a member today at Radiolab.org/donate.     You can read The Transition Integrity Project's report here.